ストックスクリーナーアプリを入手
9.19
1.32%
0.12
前日終値:
$9.07
開ける：
$9.15
24時間の取引高:
2.57M
Relative Volume:
1.14
時価総額：
$2.76B
収益：
$493.67M
当期純損益:
$-104.69M
株価収益率:
-27.03
EPS:
-0.34
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
-5.94%
1か月 パフォーマンス:
-3.36%
6か月 パフォーマンス:
-23.99%
1年 パフォーマンス:
-32.23%
1日の値動き範囲:
$9.02
$9.26
1週間の範囲:
$9.02
$10.00
52週間の値動き範囲:
$8.785
$14.02
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
FOLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.19 | 2.76B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Transcend Capital Advisors LLC Acquires 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India
Amicus Therapeutics files prospectus for stock sales - Investing.com India
Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Wells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net
Amicus Therapeutics Inc FOLD - Stockhouse Publishing
BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating - Investing.com Canada
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm - Milton Daily Standard
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates - Yahoo Finance
AMICUS THERAPEUTICS Earnings Results: $FOLD Reports Quarterly Earnings - Nasdaq
Amicus Therapeutics Turns To Q4 Profit; Product Sales Grow 30% - Nasdaq
Amicus Therapeutics' Q4 Non-GAAP Earnings, Net Product Revenue Rise -February 19, 2025 at 07:34 am EST - Marketscreener.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Peregrine Capital Management LLC - MarketBeat
Amicus Therapeutics Reports Strong 2024 Financial Results and Positive Outlook for 2025 - TradingView
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates - GlobeNewswire
Amicus Therapeutics (FOLD) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Nigeria
Amicus Therapeutics FY 2024 Earnings Preview - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Trimmed by Fiera Capital Corp - MarketBeat
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm - EIN News
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Buy" at StockNews.com - MarketBeat
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - MSN
Unfolding Amicus - RTTNews
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $16.88 - Defense World
abrdn plc Cuts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 - GlobeNewswire
Amicus Therapeutics to Host Conference Call for Full-Year 2024 Financial Results on February 19, 2025 - Nasdaq
Amicus Therapeutics (FOLD) Sets Critical 2024 Earnings ReviewKey Details for Rare Disease Investors - StockTitan
27,523 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Tempus Wealth Planning LLC - MarketBeat
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):